- Jury Finds in Favor of Wyeth in Four Cases -
MADISON, N.J., Aug. 12 /PRNewswire-FirstCall/ -- Wyeth (NYSE: WYE)
announced today that the jury deliberating over four combined diet drug cases
in the Court of Common Pleas of the First Judicial District of Pennsylvania
has returned a verdict in favor of the Company. The four cases were Florence
Ford, Lynette Hargrove, Cynthia Nixon and Robin Steward v. Wyeth.
The plaintiffs in these cases alleged heart valve injury from the use of
the diet drugs Pondimin and Redux, drugs once marketed by Wyeth. The jury
found that Wyeth had not been negligent in its marketing of Pondimin or Redux,
and also found that the plaintiffs had failed to prove they had a heart valve
injury due to their use of these drugs. This trial began on July 20, 2004
before The Honorable Alfred J. DiBona, Jr.
Wyeth is one of the world's largest research-driven pharmaceutical and
health care products companies. It is a leader in the discovery, development,
manufacturing, and marketing of pharmaceuticals, vaccines, biotechnology
products and nonprescription medicines that improve the quality of life for
people worldwide. The Company's major divisions include Wyeth
Pharmaceuticals, Wyeth Consumer Healthcare and Fort Dodge Animal Health.
SOURCE Wyeth
 back to top
Related links:
http://www.wyeth.com
CONTACT:
Media, Lowell Weiner, Wyeth, +1-973-660-5013,
Douglas Petkus, Wyeth Pharmaceuticals, +1-484-865-5140, or
Investor, Justin Victoria of Wyeth, +1-973-660-5340
|
